NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Volkmar Müller
Universität Hamburg - Hamburg / Germany
Others
AD Scientific Index ID: 4704654
University of Hamburg
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Volkmar Müller's MOST POPULAR ARTICLES
1-)
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch systemS Riethdorf, H Fritsche, V Müller, T Rau, C Schindlbeck, B Rack, ...Clinical cancer research 13 (3), 920-928, 200714642007
2-)
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancerRK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...New England Journal of Medicine 382 (7), 597-609, 20207472020
3-)
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsM Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ...Clinical Cancer Research 17 (18), 6012-6020, 20117222011
4-)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...The Lancet Oncology 21 (4), 519-530, 20207172020
5-)
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast …M Untch, PA Fasching, GE Konecny, S Hasmüller, A Lebeau, ...Journal of Clinical Oncology 29 (25), 3351-3357, 20116132011
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept